Inflammation in mild cognitive impairment due to Parkinson's disease, Lewy body disease, and Alzheimer's disease.

Authors:
Eleanor King
Eleanor King
University of Adelaide
Paul Donaghy
Paul Donaghy
Belfast City Hospital
United Kingdom
Rachael A Lawson
Rachael A Lawson
Newcastle University
United Kingdom
Christopher M Morris
Christopher M Morris
Newcastle University
United Kingdom
Nicola Barnett
Nicola Barnett
Institute for Ageing and Institute of Neuroscience
Boston | United States
Kirsty Olsen
Kirsty Olsen
Institute of Neuroscience

Int J Geriatr Psychiatry 2019 Apr 16. Epub 2019 Apr 16.

Institute of Neuroscience, Campus for Aging and Vitality, Newcastle upon Tyne, UK.

Background: Inflammation appears to play a role in the progression of neurodegenerative diseases. However, little is known about inflammation during early stages of cognitive decline or whether this differs in different disease groups. We sought to investigate this by assessing the inflammatory profile in patients with Parkinson disease with the early stages of cognitive impairment (PD-MCI), patients with prodromal Alzheimer disease (MCI-AD), prodromal Lewy body disease (MCI-LB), and controls.

Methods: We obtained venous blood samples from participants with PD-MCI (n = 44), PD-normal cognition (n = 112), MCI-LB (n = 38), MCI-AD (n = 21), and controls (n = 84). We measured 10 cytokines using Meso Scale Discovery V-Plex Plus including interferon gamma, interleukin (IL)-10, IL-12p70, IL-13, IL-1beta, IL-2, IL-4, IL-6, IL-8, and tumour necrosis factor alpha. High-sensitivity C-reactive protein was measured.

Results: There was a higher level of inflammation in patients with MCI-AD and MCI-LB compared with controls. PD noncognitively impaired had higher inflammatory markers than controls, but there was no difference between PD-MCI and controls. There was a decrease in inflammatory markers with increasing motor severity based on the Unified Parkinson's Disease Rating Scale.

Conclusions: Inflammation may be involved in the onset of cognitive decline in patients with MCI-AD and MCI-LB but appears to be less prominent PD-MCI albeit in a small data set. This suggests that anti-inflammatory medications may have most benefit at the earliest stages of neurodegenerative diseases. For PD cases, this might be in advance of the development of MCI.

Download full-text PDF

Source
http://dx.doi.org/10.1002/gps.5124DOI Listing
April 2019
11 Reads

Publication Analysis

Top Keywords

body disease
8
parkinson's disease
8
cognitive decline
8
stages cognitive
8
neurodegenerative diseases
8
early stages
8
disease
8
lewy body
8
inflammatory markers
8
cognitive impairment
8
patients mci-ad
8
mci-ad mci-lb
8
inflammation
5
alpha high-sensitivity
4
factor alpha
4
necrosis factor
4
il-6 il-8
4
il-8 tumour
4
mci-lb compared
4
tumour necrosis
4

References

(Supplied by CrossRef)
A meta‐analysis of cytokines in Alzheimer's disease
Swardfager W et al.
Biol Psychiatry 2010

Similar Publications